|
⚲
|
| Keyboard |
| Verduyn-van Weegen Felice Isabel
✚
|
|
|---|---|
| CIK # | 0002094941 |
| EDGAR Form | CIK | 2011 - 2026 |
|---|---|---|
| 3 | [0002094941] | |
| 4 | [0002094941] |
| Form 3/4/5 Subject | 2011 - 2026 |
|---|---|
| Verduyn-van Weegen Felice Isabel | |
| Agomab Therapeutics NV | |
| Evommune Inc |
| Insider Transaction (Form 3/4/5) | Date | Action | Shares | Price | Value ($) |
|---|---|---|---|---|---|
|
Evommune Inc EVMN
Common Stock
|
2026-02-17 | Grant | 358,680 | $27.88 | 9,999,998 |
|
Evommune Inc EVMN
Common Stock
|
2025-11-07 | Conversion | 3,367,133 | ||
|
Evommune Inc EVMN
Common Stock
|
2025-11-07 | Buy | 1,562,500 | $16.00 | 25,000,000 |
|
Evommune Inc EVMN
Series B Preferred Stock · derivative
|
2025-11-07 | Conversion | 5,090,000 | ||
|
Evommune Inc EVMN
Series C Preferred Stock · derivative
|
2025-11-07 | Conversion | 6,585,011 | ||
|
Evommune Inc EVMN
Series A Preferred Stock · derivative
|
2025-11-07 | Conversion | 15,493,466 |